A detailed history of Capital International Investors transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Capital International Investors holds 2,109,390 shares of ASND stock, worth $276 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
2,109,390
Previous 2,104,298 0.24%
Holding current value
$276 Million
Previous $287 Million 9.77%
% of portfolio
0.06%
Previous 0.06%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$113.0 - $153.43 $575,396 - $781,265
5,092 Added 0.24%
2,109,390 $315 Million
Q2 2024

Aug 13, 2024

SELL
$121.07 - $153.67 $10.5 Million - $13.4 Million
-87,014 Reduced 3.97%
2,104,298 $287 Million
Q1 2024

May 14, 2024

BUY
$123.45 - $159.4 $1.24 Million - $1.6 Million
10,044 Added 0.46%
2,191,312 $331 Million
Q4 2023

Feb 13, 2024

BUY
$86.1 - $127.36 $1.1 Million - $1.63 Million
12,825 Added 0.59%
2,181,268 $275 Million
Q3 2023

Nov 13, 2023

BUY
$86.5 - $103.97 $15 Million - $18 Million
173,172 Added 8.68%
2,168,443 $203 Million
Q2 2023

Aug 11, 2023

BUY
$69.96 - $97.84 $431,303 - $603,183
6,165 Added 0.31%
1,995,271 $178 Million
Q1 2023

May 15, 2023

BUY
$104.9 - $126.78 $44.2 Million - $53.4 Million
421,109 Added 26.86%
1,989,106 $213 Million
Q4 2022

Feb 14, 2023

BUY
$99.42 - $131.97 $24.7 Million - $32.8 Million
248,546 Added 18.84%
1,567,997 $191 Million
Q3 2022

Nov 14, 2022

BUY
$84.03 - $110.23 $1.04 Million - $1.37 Million
12,430 Added 0.95%
1,319,451 $136 Million
Q2 2022

Aug 15, 2022

BUY
$78.08 - $117.61 $82.8 Million - $125 Million
1,060,819 Added 430.87%
1,307,021 $122 Million
Q1 2022

May 16, 2022

BUY
$102.18 - $135.75 $25.2 Million - $33.4 Million
246,202 New
246,202 $28.9 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.3B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Capital International Investors Portfolio

Follow Capital International Investors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.